natgillin/translations-raw huggingface dataset:
Clearance may be reduced in patients with low creatinine clearance.
Klirens može biti smanjen u pacijenata s niskim klirensom kreatinina.
Clearance of cinacalcet is higher in smokers than in non-smokers, likely due to induction of CYP1A2- mediated metabolism.
Klirens sinakalceta veći je u pušača nego kod nepušača, najvjerojatnije zbog povećanja metabolizma posredovanog CYP1A2.
Clearance of cinacalcet may be lower in women than in men.
Klirens sinakalceta može biti manji u žena nego u muškaraca.
Clearance of dabigatran in patients with renal insufficiency may take longer.
Klirens dabigatrana u bolesnika s insuficijencijom bubrežne funkcije može biti usporen.
Clearance of darbepoetin alfa is 1.9 ml/hr/kg (SD 0.56) and the volume of distribution (Vss) is approximately equal to plasma volume (50 ml/kg).
Klirens darbepoetina alfa je 1,9 ml/sat/kg (SD 0,56) i volumen distribucije (Vss) je otprilike jednak volumenu u plazmi (50 ml/kg).
Clearance of GL-3 in the superficial skin vascular endothelium was achieved in all patients who had accumulated GL-3 at baseline.
Klirens GL-3 u površinskom krvožilnom endotelu kože postignut je u svih bolesnika u kojih je na početku liječenja postojala kumulacija GL-3.
Clearance of HCV may lead to increased replication of HBV in patients who are HCV/HBV co-infected.
Klirens HCV-a može dovesti do povećane replikacije HBV-a u bolesnika koji imaju koinfekciju HCV- om/HBV-om.
Clearance of the virus was seen for all genotypes including genotype 3.
Uklanjanje virusa zabilježeno je kod svih genotipova, uključujući genotip 3.
Clearance of tolvaptan is not significantly affected by age.
Životna dob ne utječe bitno na klirens tolvaptana .
Clearance was 0.0145 L/h with a range of 0.00904 – 0.0229 for no increase in anti-pegloticase antibodies and 0.0193 L/h with a range of 0.00675 – 0.0340 for an increase in anti-pegloticase antibodies.
Klirens je iznosio 0,0145 l/h s rasponom 0,00904-0,0229 u bolesnika bez porasta razine protutijela na peglotikazu i 0,0193 l/h s rasponom 0,00675-0,0340 u bolesnika s porastom razine protutijela na peglotikazu.
Clearance was 12.7 l/h in PV patients, with a 42% inter-subject variability and no relationship was apparent between oral clearance and gender, patient age or race based on a population pharmacokinetic evaluation in PV patients.
Klirens je bio 12,7 l/h u bolesnika s PV-om, uz varijabilnost između ispitanika od 42% te nije bilo očite povezanosti između oralnog klirensa i spola, bolesnikove dobi ili rase, temeljeno na procjeni populacijske farmakokinetike u bolesnika s PV-om.
Clearance was also very high in patients whose liver is not working properly (Child-Pugh class B cirrhosis), when treated with Epclusa in combination with ribavirin.
Uklanjanje je također bilo vrlo uspješno u bolesnika čija jetra ne funkcionira normalno (ciroza Child-Pugh stadija B) nakon liječenja kombinacijom lijeka Epclusa i ribavirina.
Clearance was dose- and time-independent.
Klirens nije ovisio o dozi i o vremenu.
Clearance was not affected by age (range 23-88 years), gender, concomitant use of budesonide or dacarbazine, performance status, HLA-A2*0201 status, mild hepatic impairment, renal impairment, immunogenicity, and previous anticancer therapy.
Na klirens nisu utjecali dob (raspon, -23-88 godina), spol, istovremeno uzimanje budesonida ili dakarbazina, opće stanje bolesnika, HLA-A2*0201 status, blago oštećenje funkcije jetre, oštećenje funkcije bubrega, imunogenost ni prethodna antitumorska terapija.
Clearance, weight-normalised clearance, and AUC were not appreciably different among patients with different body weights, including those weighing ≥125 kg.
Klirens, klirens normaliziran s obzirom na težinu i AUC nisu bili bitno različiti među bolesnicima s različitom tjelesnom težinom, uključujući i one s težinom ≥125 kg.
Clearance: 0.665 ± 0.0493 l/h (Mean ± SE)
Klirens: 0,665 ± 0,0493 l/h (srednja vrijednost ± SE)
Cleared from plasma (days)***
Klirens plazme (dana)
CLEOPATRA (WO20698) is a multicentre, randomised, double-blind, placebo-controlled phase III clinical trial conducted in 808 patients with HER2-positive metastatic or locally recurrent unresectable breast cancer.
CLEOPATRA (WO20698) je multicentrično, randomizirano, dvostruko slijepo, placebom kontrolirano kliničko ispitivanje faze III, provedeno u 808 bolesnika s HER2 pozitivnim metastatskim ili lokalno recidivirajućim neresektabilnim rakom dojke.
Click 10 seconds Keep holding the clear base firmly against your skin.
Klik 10 sekundi Nastavite držati prozirnu bazu čvrsto priljubljenom uz kožu.
Clicking Starts
Klik počinje
clicks
škljocaja
cLife-threatening is a subset of TIMI Major bleeding and includes the types indented below.
hemoglobina ≥ 5 g/dl. c Krvarenje opasno po život je podskupina značajnih krvarenja prema TIMI kriterijima i obuhvaća oblike krvarenja prikazane uvučeno u sljedećim retcima.
CLINCAL PARTICULARS
KLINIČKI PODACI
Clinic SBP: LS Mean Change from Baseline (BL) to Week 6 (mm Hg) (LOCF)
Klinički mjereni sistolički krvni tlak: LS prosječna promjena od početne vrijednosti do 6. tjedna (mm Hg) (LOCF)
Clinical
Preporučuje se kliničko
Clinical Adverse Reactions (H1N1)v Studies
Klinička ispitivanja nuspojava (H1N1)v
clinical and laboratory
klinički i laboratorijski nadzor
Clinical and laboratory
Preporučuje se kliničko i
Clinical and surveillance data: Natural mutations associated with reduced susceptibility to oseltamivir in vitro have been detected in influenza A and B viruses isolated from patients without exposure to oseltamivir.
Klinički podaci i opažanja: Prirodno nastale mutacije koje su bile povezane sa smanjenom osjetljivošću na oseltamivir in vitro nađene su u izolatima virusa gripe A i B u bolesnika koji nisu bili izloženi oseltamiviru.
Clinical and virological efficacy endpoints were evaluated separately in the HBeAg-positive and HBeAg-negative patient populations.
Mjere ishoda kliničke i virološke djelotvornosti ispitivane su odvojeno u populacijama HBeAg- pozitivnih i u HBeAg-negativnih bolesnika.
Clinical aspects:
Klinički aspekti:
Clinical assessment of follitropin alfa indicates that its daily doses, regimens of administration and treatment monitoring procedures should not be different from those currently used for urinary FSH-containing medicinal products.
Klinička procjena folitropina alfa upućuje na to da se njegove dnevne doze, režimi davanja i metode praćenja terapije ne bi trebale razlikovati od onih koje se trenutačno koriste za preparate koji sadrže urinarni FSH.
Clinical Benefit Rate (CBR)
Stopa kliničke dobiti
Clinical Benefit Rate (ORR+MR) [n(%)]
Stopa kliničke koristi (ORR+MR) [n (%)]
Clinical Benefit Rate was defined as complete plus partial response plus stable disease for 6 months.
Stopa kliničke dobiti definirana je kao potpuni plus djelomični odgovor plus stabilna bolest kroz ≥6 mjeseci
Clinical benefit ratec
Stopa kliničke dobitic
Clinical Breakpoints S ≤ 0.25 mg/l; R > 0.25 mg/l
Kliničke granične vrijednosti S ≤ 0,25 mg/l; R > 0,25 mg/l
Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with imatinib (see section 4.5).
U tireidektomiranih bolesnika i koji primaju nadomjesnu terapiju levotiroksinom zabilježeni su klinički slučajevi hipotireoze tijekom liječenja imatinibom (vidjeti dio 4.5).
Clinical characteristics of never smoker, adenocarcinoma histology, and female gender have been shown to be independent predictors of positive EGFR mutation status in a multivariate analysis of 786 Caucasian patients from gefitinib studies* (see Table 7).
U multivarijatnoj analizi 786 bolesnika bijele rase iz ispitivanja s gefitinibom*, pokazalo se da su klinička obilježja da osoba nikada nije pušila, da ima histologiju adenokarcinoma i da je ženskog spola neovisni pretkazatelji pozitivnog statusa mutacije EGFR (vidjeti Tablicu 7).
Clinical chemistry
Klinička biokemija
Clinical chemistry abnormalities: clinical chemistry abnormalities (Grade 3 or 4) potentially related to treatment with fosamprenavir with ritonavir and reported in greater than or equal to 1 % of adult patients, included: increased ALT (common), AST (common), serum lipase (common) and triglycerides (common).
Abnormalnosti kliničkih biokemijskih parametara: abnormalnosti kliničkih biokemijskih parametara (3. i 4. stupnja) potencijalno povezanih s terapijom fosamprenavirom s ritonavirom, a koje su prijavljene u 1% ili više odraslih bolesnika, uključivale su: povećane razine ALT-a (često), AST-a (često), lipaze u serumu (često) i triglicerida (često).
Clinical Comments
(1,13-1,80)
Clinical Comments
1,28 (0,92-1,79)
Clinical Comments
3,26 (2,06-5,16)
Clinical Comments
do 50%.
Clinical Comments
i ritonavir
Clinical Comments
IMUNOSUPRESIVI
Clinical Comments
Nije potrebno
Clinical Complete Response (CCR) %
Potpuni klinički odgovor (CCR)
Clinical Cure, mITT Population
Kliničko izlječenje, populacija mITT
Clinical data (semen analyses and inhibin B levels – [a glycoprotein produced by Sertoli cells – used as a surrogate marker of testicular function]) showed no evidence of altered testicular function.
Klinički podaci (analiza sjemena i razine inhibina B – [glikoproteina kojeg stvaraju Sertolijeve stanice i koji se koristi kao surogatni biljeg funkcije testisa]) nisu pokazali promjene u funkciji testisa.
Clinical data are not yet available in this population (see section 4.2).
Klinički podaci još nisu dostupni za ovu populaciju (vidjeti dio 4.2).
Clinical data confirm that CYP3A4 is responsible for the N- dealkylation of buprenorphine.
Klinički podaci potvrđuju da je CYP3A4 odgovoran za N-dealkilaciju buprenorfina.
Clinical data described below suggest that the risk for clinically meaningful interactions by co- administered medicinal products is low.
Klinički podaci, opisani u nastavku, ukazuju na nizak rizik od klinički značajnih interakcija pri istodobnoj primjeni s drugim lijekovima.
Clinical data described below suggest that the risk for clinically meaningful interactions by co- administered medicinal products is low.
U nastavku opisani klinički podaci ukazuju da je rizik od klinički značajnih interakcija kod istodobne primjene lijekova malen.
Clinical data described below suggest that the risk for clinically meaningful interactions by co-administered medicinal products is low.
Klinički podaci, opisani u nastavku, ukazuju na nizak rizik od klinički značajnih interakcija pri istodobnoj primjeni s drugim lijekovima.
Clinical data described below suggest that the risk for clinically meaningful interactions by coadministered medicinal products is low.
U nastavku opisani klinički podaci ukazuju da je rizik od klinički značajnih interakcija u istovremenoj primjeni lijekova nizak.
Clinical data described below suggest that the risk for clinically meaningful interactions with co-administered medicinal products is low.
Klinički podaci opisani u nastavku upućuju na to da je rizik od klinički značajnih interakcija s istodobno primijenjenim lijekovima nizak.
Clinical data from MTC
Klinički podaci za medularni karcinom štitnjače
Clinical data from trials in other patient populations
Klinički podaci iz ispitivanja na drugim bolesnicima
Clinical data from trials in other patient populations
Klinički podaci iz ispitivanja na drugim populacijama bolesnika
Clinical data however indicate that the overall incidence of adverse events is increased if patients are simultaneously exposed to tasonermin and interferon-gamma.
Međutim, klinički podaci pokazuju da je ukupna incidencija štetnih događaja povećana ako se bolesnici istovremeno izlažu tasonerminu i interferonu- gama.
Clinical data in children less than 6 years of age who received two doses of Pandemic influenza vaccine H5N1, indicate an increase in frequency of fever (axillary≥38°C) after the administration of the second dose.
Klinički podaci u djece mlađe od 6 godina koja su primila dvije doze Cjepiva protiv pandemijske influence H5N1 ukazuju na povećanu učestalost vrućice (≥ 38ºC aksilarno) nakon primjene druge doze.
Clinical data in paediatric patients has demonstrated that patients receiving r-HuEPO two or three times weekly may be converted to once weekly Aranesp, and those receiving r-HuEPO once weekly may be converted to once every other week Aranesp.
Kliničke studije su pokazale da pedijatrijski bolesnici koji primaju r-HuEPO 2 ili 3 puta tjedno mogu prijeći na primjenu Aranespa jednom tjedno, a oni koji primaju r-HuEPO jednom tjedno mogu prijeći na primjenu Aranespa jednom svaka 2 tjedna.
Clinical data in renal cell carcinoma
Klinički podaci za karcinom bubrežnih stanica
Clinical data is very limited (n = 3) for CML patients with moderate renal impairment receiving an escalated dose of 600 mg bosutinib.
Klinički podaci su vrlo ograničeni (n = 3) u bolesnika s KML-om i umjerenim oštećenjem funkcije bubrega koji primaju povećanu dozu od 600 mg bosutiniba.
Clinical data obtained from a limited number of patients also indicate that adult PID patients may tolerate an infusion rate of up to 8 ml/kg BW/hr.
Klinički podaci dobiveni u malog broja bolesnika također ukazuju da odrasli bolesnici s primarnom imunodeficijencijom (PID) mogu podnijeti brzinu infuzije do 8 ml/kg TM/sat.
Clinical data on fertility are not available for tipranavir.
Nema odgovarajućih podataka o primjeni tipranavira u trudnica.
Clinical data on treatment in immunocompromised patients is not available, but systemic risks are not expected since ingenol mebutate is not absorbed systemically.
Klinički podaci o liječenju u imunokompromitiranih bolesnika nisu dostupni, no ne očekuju se sistemski rizici budući da se ingenol mebutat ne apsorbira sistemski.
clinical data suggest that
klinički podaci ukazuju da
Clinical data suggest that after 24 to 48 months of treatment with Rebif 44 micrograms, approximately 13 to 14% of patients develop persistent serum antibodies to interferon beta-1a.
Klinički podaci ukazuju na razvoj perzistirajućih serumskih protutijela na interferon beta-1a kod približno 24% bolesnika nakon 13 do 14% mjeseci liječenja Rebifom 44 mikrograma.
Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with Lojuxta, but whether histological sequelae remain is unknown, especially after long-term use.
Klinički podaci upućuju na to je nakupljanje masti u jetri reverzibilno nakon prekida liječenja Lojuxtom, ali ostaje nepoznato ima li histoloških posljedica, osobito nakon dugotrajne primjene.
Clinical data suggest that the pharmacokinetics of statins are largely unaltered by the co-administration of tacrolimus.
Klinički podaci upućuju na to da farmakokinetika statina uglavnom nije promijenjena pri istvremenoj j primjeni s takrolimusom.
Clinical data suggest that the pharmacokinetics of statins are largely unaltered by the co-administration of tacrolimus.
Sudeći prema kliničkim podacima, farmakokinetika statina uglavnom nije promijenjena pri istodobnoj primjeni takrolimusa.
Clinical data were collected for 30 days of treatment.
Klinički podaci prikupljali su se tijekom 30 dana liječenja.
clinical data.
Dolutegravir
clinical data.
se ne preporučuje.
Clinical Description of abacavir HSR
Klinički opis reakcije preosjetljivosti na abakavir
Clinical description of HSRs
Klinički opis reakcija preosjetljivosti
Clinical drug-drug interactions studies in healthy subjects indicated a reduced exposure to delamanid, of up to 45% following 15 days of concomitant administration of the strong inducer of cytochrome P450 (CYP) 3A4 (Rifampicin 300 mg daily) with delamanid (200 mg daily).
Klinička ispitivanja interakcija lijekova u zdravih ispitanika ukazuju na smanjenu izloženost delamanidu do 45% nakon 15 dana istodobne primjene jakog induktora citokroma P450 (CYP) 3A4 (Rifampicin 300 mg dnevno) s delamanidom (200 mg dnevno).
Clinical Efficacy
Klinička djelotvornost:
Clinical efficacy
Klinička učinkovitost
Clinical efficacy
Tardivna diskinezija
Clinical efficacy and in-vivo recovery of Nuwiq was not affected in this patient.
Kod ovog bolesnika nije bilo utjecaja na kliničku učinkovitost i oporavak in vivo za lijek Nuwiq.
Clinical efficacy and safety (DVT/PE prevention)
Klinička učinkovitost i sigurnost (prevencija DVT/PE-a)
Clinical efficacy and safety (DVT/PE treatment)
Klinička djelotovornost i sigurnost (liječenje DVT/PE-a)
Clinical efficacy and safety (SPAF)
Klinička djelotvornost i sigurnost (prevencija MU i SE kod AF)
Clinical efficacy and safety in allergic asthma
Klinička djelotvornost i sigurnostu alergijskoj astmi
Clinical efficacy and safety in Parkinson’s disease
Klinička djelotvornost i sigurnost kod Parkinsonove bolesti
Clinical efficacy and safety in Parkinson’s disease
Klinička djelotvornost i sigurnost u Parkinsonovoj bolesti
Clinical efficacy and safety in Restless Legs Syndrome
Klinička djelotvornost i sigurnost u sindromu nemirnih nogu
Clinical efficacy and safety studies of Zavicefta have been conducted in cIAI and cUTI only.
Klinička ispitivanja djelotvornosti i sigurnosti lijeka Zavicefta provedena su samo kod kompliciranih intraabdominalnih infekcija i kompliciranih infekcija mokraćnog sustava.
Clinical efficacy and safety Treatment-experienced adult patients Pivotal studies
Klinička djelotvornost i sigurnost Prethodno liječeni odrasli bolesnici Osnovna ispitivanja
Clinical efficacy and safety – Adults
Djelotvornost i sigurnost u kliničkoj primjeni - odrasli
Clinical efficacy and safety – paediatric population
Klinička djelotvornost i sigurnost - pedijatrijska populacija
Clinical efficacy defined as partial or complete response, has been demonstrated for Aspergillus spp. including A. flavus, A. fumigatus, A. terreus, A. niger, A. nidulans, Candida spp., including C. albicans, C. glabrata, C. krusei, C. parapsilosis and C. tropicalis and limited numbers of C. dubliniensis, C. inconspicua and C. guilliermondii, Scedosporium spp., including S. apiospermum, S. prolificans and Fusarium spp.
Klinička je djelotvornost, definirana kao djelomičan ili potpun odgovor, dokazana za vrste iz roda Aspergillus uključujući A. flavus, A. fumigatus, A. terreus, A. niger, A. nidulans, vrste iz roda Candida uključujući C. albicans, C. glabrata, C. krusei, C.parapsilosis i C. tropicalis i za ograničen broj C. dubliniensis, C. inconspicua i C. guilliermondii, vrste iz roda Scedosporium uključujući S. apiospermum, S. prolificans te vrste iz roda Fusarium.
Clinical efficacy has been demonstrated across the range 111 to 185 MBq.
Klinička djelotvornost dokazana je za raspon od 111 do 185 Mbq.
Clinical efficacy has been demonstrated for susceptible isolates in the approved clinical indications.
Klinička je djelotvornost dokazana za osjetljive izolate u odobrenim kliničkim indikacijama.
Clinical efficacy has been demonstrated for the following Aspergillus species: Aspergillus fumigatus, flavus, A. niger, and A. terreus (see further below).
Klinička djelotvornost dokazana je za sljedeće vrste gljivica Aspergillus: Aspergillus fumigatus, flavus, A. niger i A. terreus (vidjeti nastavak).
Clinical efficacy has been demonstrated for the following Aspergillus species: Aspergillus fumigatus, flavus, A. niger, and A. terreus(see further below).
Klinička djelotvornost dokazana je za sljedeće vrste gljivica Aspergillus: Aspergillus fumigatus, A. flavus, A. niger i A. terreus (vidjeti nastavak).
Clinical efficacy in bipolar I disorder
Klinička djelotvornost u bipolarnom poremećaju tipa I
Clinical efficacy in homozygous familial hypercholesterolaemia
Klinička djelotvornost kod homozigotne obiteljske hiperkolesterolemije
Clinical efficacy in osteoporosis associated with long-term systemic glucocorticoid therapy
Klinička djelotvornost u osteoporozi povezanoj s dugotrajnim sistemskim liječenjem glukokortikoidima
Clinical efficacy in patients with bone metastases from solid tumours
Klinička djelotvornost u bolesnika s koštanim metastazama solidnih tumora
Clinical efficacy in previously untreated mantle cell lymphoma (MCL)
Klinička djelotvornost kod prethodno neliječenog limfoma plaštenih stanica (MCL)
Clinical efficacy in previously untreated multiple myeloma
Klinička djelotvornost u prethodno neliječenih bolesnika s multiplim mijelomom
Clinical efficacy in relapsed or refractory multiple myeloma
Klinička djelotvornost kod relapsa ili refraktornog multiplog mijeloma
Clinical efficacy in the treatment of Paget’s disease of the bone
Klinička djelotvornost u liječenju Pagetove bolesti kosti
Clinical efficacy in women aged 15 to 25 years
Klinička djelotvornost u žena u dobi od 15 do 25 godina
Clinical efficacy in women aged 26 years and older
Klinička djelotvornost u žena u dobi od 26 godina i više
Clinical efficacy of Descovy in treatment-naïve patients was also established from a study conducted with emtricitabine and tenofovir alafenamide (10 mg) when given with darunavir (800 mg) and cobicistat as a fixed-dose combination tablet (D/C/F/TAF).
Klinička djelotvornost lijeka Descovy u liječenju bolesnika koji prethodno nisu bili liječeni takoĎer je ustanovljena u ispitivanju provedenom s emtricitabinom i tenofoviralafenamidom (10 mg) kad su se davali u fiksnoj kombinaciji s darunavirom (800 mg) i kobicistatom u jednoj tableti (D/C/F/TAF).
Clinical efficacy of Odefsey was established from studies conducted with emtricitabine+tenofovir alafenamide when given with elvitegravir+cobicistat as an E/C/F/TAF FDC tablet; and from studies with rilpivirine when given with FTC/TDF as individual components or as a FTC/RPV/TDF FDC tablet.
Klinička djelotvornost lijeka Odefsey ustanovljena je na temelju ispitivanja provedenih s emtricitabinom i tenofoviralafenamidom kada se daju s elvitegravirom i kobicistatom kao E/C/F/TAF tableta s fiksnom kombinacijom; i na temelju ispitivanja s rilpivirinom kada se daje s FTC/TDF kao individualne komponente ili kao FTC/RPV/TDF tableta s fiksnom kombinacijom.
Clinical efficacy TDM4370g/BO21977
Klinička djelotvornost TDM4370g/BO21977
Clinical efficacy was maintained during the follow-up periods of 6 and 12 months after the last PDT.
Klinička djelotvornost bila je održana tijekom razdoblja praćenja od 6 i 12 mjeseci nakon zadnje fotodinamske terapije.
Clinical efficacy was maintained during the follow-up periods of 6 and 12 months after the last photodynamic therapy.
Klinička djelotvornost je zadržana tijekom razdoblja praćenja od 6 i 12 mjeseci nakon zadnjeg fotodinamske terapije.
Clinical efficacy was re-assessed at follow-up visits 6 and 12 months after the last photodynamic therapy.
Klinička djelotvornost je ponovo ocijenjena na kontrolnim pregledima 6 i 12 mjeseci nakon zadnjeg fotodinamskog liječenja.
Clinical efficacy with lamivudine
Klinička djelotvornost lamivudina
Clinical efficacy with raltegravir
Klinička djelotvornost raltegravira
Clinical efficacy with subcutaneous administration of VELCADE in patients with relapsed/refractory multiple myeloma
Klinička djelotvornost uz supkutanu primjenu VELCADEa u bolesnika s relapsnim/refraktornim multiplim mijelomom
Clinical endpoints
Kliničke ishodi
Clinical Endpointsa
Kliničke krajnje točkea
Clinical evidence of inhibition of the late sodium current by ranolazine is provided by a significant shortening of the QTc interval and an improvement in diastolic relaxation in an open-label study of 5 patients with a long QT syndrome (LQT3 having the SCN5A ∆KPQ gene mutation).
Klinički dokaz inhibicije kasnog protoka natrija pomoću ranolazina nalazi se u značajnom skraćenju QTc intervala i poboljšanju dijastoličke relaksacije u otvorenoj studiji na 5 bolesnika sa sindromom dugog QT (LQT3 sa SCN5A ∆KPQ mutacijom gena).
Clinical experience beyond 52 weeks is not available (see section 5.1).
Nema kliničkog iskustva s liječenjem duljim od 52 tjedna (vidjeti dio 5.1).
Clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Kliničko iskustvo ne pokazuje razliku u odgovoru starijih i mlađih bolesnika, no ne može se isključiti veća osjetljivost nekih starijih pojedinaca.
Clinical experience in granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis
Klinička iskustva u liječenju granulomatoze s poliangitisom (Wegenerova granulomatoza) i mikroskopskog poliangitisa
Clinical experience in Non-Hodgkin’s lymphoma and in chronic lymphocytic leukaemia
Klinička iskustva u liječenju ne-Hodgkinova limfoma i kronične limfocitne leukemije